PepGen Inc. (PEPG)
PEPGNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$5.00
-0.2650 (-5.04%) today
Regular session, Nov 12, 2:33 PM ET
- Market cap
- $345.96m
- P/E
- –
- EPS, last 4 quarters
- $-1.07
- Dividend yield
- –
- Day range
- $4.84 to $5.34
- 52-week range
- $1.31 to $7.80
- Average volume
- –
- Previous close
- $5.26
Analysts
4 coveringBuy3 buy, 0 hold, 1 sell
Targets a year out average $14.17, +183.7% from here
Earnings
next estimate $-0.3300Next report
Dec 2025
+32.5%
Mar 2026
+16.1%
Jun 2026
+13.3%
Sep 2026
-3.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$19.70m | -$18.94m | -$18.94m | -$20.38m |
| Net income | -$18.34m | -$17.76m | -$17.81m | -$19.39m |
News
8 latest- PepGen Prices $125 Mln Offering Of 25 Mln Shares At $5.00 Per Share; Stock Up RTTNews · 13 hours ago
- Biotech Stocks In Focus: PEPG Jumps 114%, ZURA Rises 15%, NTHI Gains 13% RTTNews · 2 days ago
- PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · May 20, 2026
- PepGen (PEPG) Upgraded to Buy: Here's What You Should KnowZacks · May 13, 2026
- Oppenheimer Initiates Coverage of PepGen (PEPG) with Outperform RecommendationFintel · Feb 25, 2026
- How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%Zacks · Dec 10, 2025
- Sarepta's Stock Rises on Positive Updates on DM1 TherapyZacks · Nov 25, 2025
- PepGen (PEPG) Price Target Increased by 17.65% to 10.20Fintel · Nov 16, 2025
The company
PepGen Inc. is a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases. Founded on more than a decade of research and development, PepGen's Enhanced Delivery Oligonucleotide (EDO) technology leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using this EDO technology, PepGen is advancing PGN-EDODM1, a clinical candidate for the treatment of myotonic dystrophy type 1.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- pepgen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.